The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical ...

Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

Shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Boosting Klotho protein levels in mice improves physical and cognitive aging, offering potential for future longevity ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

U.S. stock futures declined on Thursday after ending higher on Wednesday. Futures of major benchmark indices were trading ...

Klotho Neurosciences, Inc. (KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it ...

NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for ...

NEW YORK, June 30, 2025 /CNW/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials ...